Home›Trial›NCT04645212
NCT04645212ACTIVE NOT RECRUITING

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

Study Summary

ADVM-022-07 is an observational long-term extension (OPTIC-EXT) study assessing safety and efficacy of ADVM-022 gene therapy product, in participants with neovascular, or exudative (wet), age-related macular degeneration (nAMD).

Conditions
Wet Age-related Macular DegenerationNeovascular Age-related Macular Degeneration
Interventions / Drugs
ADVM-022
View on ClinicalTrials.gov ↗
Sponsor
ADVM
Adverum Biotechnologies
Ophthalmology
C59/100
Study Details
Enrollment23 participants
Primary Completion—
Lead SponsorAdverum Biotechnologies, Inc.
Data Retrieved2026-04-11 02:52:31.871599+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 23 participants
Sponsor Catalyst Profile

Adverum Biotechnologies (ADVM) is the sponsoring company for this trial. BiotechSign currently grades this company C (59/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

ADVM Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.